Thoracic Radiotherapy Plus EGFR-TKI for Stage III EGFR-mutant Lung Adenocarcinoma

Patterns of Treatment Failure and Safety of Thoracic Radiotherapy Combined With EGFR-TKI in Stage III EGFR-mutant Lung Adenocarcinoma: a Multicenter Retrospective Cohort Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07857694

Enrollment

202

Registered

2026-10-05

Start date

2020-01-01

Completion date

2026-09-29

Last updated

2026-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer Stage III, EGFR Activating Mutation

Keywords

Non-small cell lung carcinoma, EGFR mutation, stage III, thoracic radiotherapy, EGFR-TKI, retrospective cohort study

Brief summary

Objective: To investigate the failure patterns, efficacy and safety of thoracic radiotherapy combined with EGFR-TKI in stage III unresectable non-small cell lung cancer harboring EGFR-sensitive mutations. Methods: This is a multicenter retrospective cohort study. Patients diagnosed with stage III unresectable EGFR-mutant non-small cell lung cancer who received thoracic radiotherapy plus EGFR-TKI between January 1, 2020 and December 31, 2024 were enrolled from five hospitals in Guangxi, including Laibin People's Hospital, The People's Hospital of Chongzuo, Liuzhou Traditional Chinese Medical Hospital, The First People's Hospital of Yulin, and The First Affiliated Hospital of Guilin Medical University. We will analyze progression patterns, progression-free survival, overall survival and treatment-related adverse events.

Interventions

RADIATIONThoracic radiotherapy

Thoracic radiotherapy with IMRT, prescribed dose 54-66 Gy / 27-33 fractions.

DRUGEGFR-TKI

EGFR tyrosine kinase inhibitors, including gefitinib, erlotinib, osimertinib, almonertinib; administered orally until disease progression or intolerable toxicity

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* 1\. Histologically confirmed lung adenocarcinoma. 2. Stage III unresectable non-small cell lung cancer. 3. Presence of EGFR sensitive mutation (exon 19 deletion or L858R). 4. Received thoracic radiotherapy combined with EGFR-TKI treatment. 5. Complete medical records available for retrospective data collection.

Exclusion criteria

* 1\. Prior thoracic radiotherapy before the current treatment course. 2. Concurrent active malignant tumor. 3. Incomplete clinical, imaging or follow-up data. 4. Received radical surgical resection for lung cancer.

Design outcomes

Primary

Measure	Time frame	Description
Pattern of treatment failure	From the start of thoracic radiotherapy until disease progression or death, whichever comes first.	The pattern of disease failure (local recurrence, regional lymph node recurrence, distant metastasis) after thoracic radiotherapy combined with EGFR-TKI.

Secondary

Measure	Time frame	Description
Progression-free survival (PFS)	Up to 5 years after radiotherapy initiation.	Time from the start of thoracic radiotherapy to disease progression or death from any cause.
Overall survival (OS)	From radiotherapy start until 90 days after completion of radiotherapy.	Time from the start of thoracic radiotherapy to death from any cause.
Treatment-related adverse events	From radiotherapy start until 90 days after completion of radiotherapy.	Incidence and grade of treatment-related adverse events.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Oct 6, 2026